TP53 and central nervous system cancer: Low-grade pediatric-type gliomas were enriched with BRAF mutations and rearrangements (39.3% and 25.8%, respectively) and FGFR1 alterations (30.3%), while TP53 alterations (39.9%) and homozygous deletion of CDKN2A/B (29.9%) were prevalent in other IDH1/2-wild-type gliomas.